Related Experiment Videos
[Endocrinologic factors in the development of benign prostatic hyperplasia]
H U Schweikert1, F Neumann, U W Tunn
1Medizinische Universitäts-Poliklinik Bonn.
Der Urologe. Ausg. A
|November 1, 1989
Summary
Benign prostatic hyperplasia (BPH) is linked to aging and testosterone. New drugs may shrink enlarged prostates and improve urinary flow without causing hypogonadism.
Area of Science:
- Urology
- Endocrinology
- Gerontology
Context:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- The development of BPH is associated with aging and the presence of a functioning testis.
- Current treatments targeting testosterone synthesis or action for BPH have limited therapeutic value due to hypogonadism symptoms.
Purpose:
- To explore novel therapeutic strategies for benign prostatic hyperplasia.
- To identify agents that can alleviate urinary outflow obstruction and reduce prostate size.
- To develop treatments that avoid the side effects of hypogonadism.
Summary:
- Benign prostatic hyperplasia (BPH) pathogenesis involves aging and testicular function.
- Testosterone-inhibiting drugs can regress enlarged prostates but cause hypogonadism.
- Emerging research suggests agents can shrink the prostate and relieve obstruction without impairing androgen action.
Impact:
- Potential for improved BPH management with fewer side effects.
- Development of targeted therapies for symptomatic relief in aging men.
- Advancement in understanding BPH pathophysiology and treatment options.